Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease
- PMID: 9024745
- DOI: 10.1016/s0002-9149(96)00684-4
Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease
Abstract
This randomized, double-blind, placebo-controlled study shows that 20-week fluvastatin treatment induces beneficial changes in the lipid panel and a shift in the fibrinolytic pathway toward activation through a decrease in tissue plasminogen activator antigen. Fluvastatin treatment causes no variation in lipoprotein(a) circulating levels.
Comment in
-
Another view of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors and the fibrinolytic system.Am J Cardiol. 1997 Oct 1;80(7):977-8. Am J Cardiol. 1997. PMID: 9382029 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
